You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK)將在歐洲肝臟研究協會2022年國際肝臟大會口頭報吿皮下注射PD-L1抗體ASC22用於慢乙肝功能性治癒IIb期臨牀試驗進展
格隆匯 06-16 08:05

格隆匯6月16日丨歌禮制藥-B(01672.HK)宣佈將於2022年 6月25日在倫敦舉行的歐洲肝臟研究協會(EASL)2022年國際肝臟大會(the International Liver Congress 2022, ILC 2022)上口頭報吿皮下注射PD-L1抗體 ASC22(恩沃利單抗)治療慢性乙型肝炎(慢乙肝)患者IIb期臨牀試驗最新結果。

EASL是世界頂尖的肝病研究醫學協會。ILC每年專業人士參會人數近10,000人,作為全球肝病學研究領域最具影響力的盛會之一,肝病領域最新研究進展、最佳實踐以及科研突破都會在這裏與業界分享。今年ILC共接受了全球各地1,993份研究摘要,其中共有9份中國研究入選口頭報吿。歌禮ASC22慢乙肝功能性治癒研究進展是此次ILC 2022唯一入選口頭報吿環節的由中國生物技術公司發起的乙型肝炎研究。

北京大學第一醫院感染疾病科主任及肝病中心主任王貴強教授將在ILC 2022上報吿ASC22 IIb期最新研究成果。此前王貴強教授及歌禮創始人、董事會主席兼首席執行官吳勁梓博士還曾受邀於美國肝病研究協會2021年會口頭報吿了ASC22 IIa 和IIb研究中期進展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account